Pluri Inc Revenue Growth Rates (PLUR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pluri Inc   (NASDAQ: PLUR)
 

PLUR's Revenue Growth by Quarter and Year

Pluri Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PLUR Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter June 0.34
3rd Quarter March 0.17
2nd Quarter December 0.20
1st Quarter September 0.32
FY 1.03





PLUR Revenue fourth quarter 2025 Y/Y Growth Comment
Pluri Inc reported decline in Revenue in the fourth quarter 2025 by -16.25% to $ 0.34 millions, from the same quarter in 2024.
The contraction in the fourth quarter 2025 Pluri Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 75.64%.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue growth. While Pluri Inc ' s Revenue fall of -16.25% ranks overall at the positon no. 572 in the fourth quarter 2025.


PLUR Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter June -16.25 % 300 % -9.09 % -
3rd Quarter March -60.47 % 514.29 % -22.22 % -60.87 %
2nd Quarter December 5.26 % 72.73 % - -
1st Quarter September -3.03 % 560 % -44.44 % -
FY   -24.07 % 309.09 % 13.79 % -

Financial Statements
Pluri Inc 's fourth quarter 2025 Revenue $ 0.34 millions PLUR's Income Statement
Pluri Inc 's fourth quarter 2024 Revenue $ 0.40 millions Quarterly PLUR's Income Statement


PLUR Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter June 97.06 % -6.98 % 42.86 % 22.22 %
3rd Quarter March -15 % 126.32 % -36.36 % -
2nd Quarter December -37.5 % -42.42 % 120 % -
1st Quarter September -20 % 230 % -54.55 % -
FY (Year on Year)   -24.07 % 309.09 % 13.79 % -


Back to PLUR Growth rate Comparisons >> Back to PLUR Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #127
Overall #572

Revenue Y/Y Growth Statistics
High Average Low
701.06 % 75.64 % -44.18 %
(Dec 31 2015)   (Jun 30 2014)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #127
Overall #572
Revenue Y/Y Growth Statistics
High Average Low
701.06 % 75.64 % -44.18 %
(Dec 31 2015)   (Jun 30 2014)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Pluri Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
99387.18 % 2750.67 % -100 %
(Mar 31 2013)  


PLUR's IV. Quarter Q/Q Revenue Comment
Pluri Inc achieved in the IV. Quarter 2025 below company average Revenue jump of 97.06% quarter on quarter, to $ 0.34 millions.

IV. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -6.98% in the IV. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Pluri Inc 's Revenue growth quarter on quarter, overall rank is 138.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #44
Overall #138
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #44
Overall #138
Revenue Q/Q Growth Statistics
High Average Low
99387.18 % 2750.67 % -100 %
(Mar 31 2013)  


PLUR's IV. Quarter Q/Q Revenue Comment
Pluri Inc achieved in the IV. Quarter 2025 below company average Revenue jump of 97.06% quarter on quarter, to $ 0.34 millions.

IV. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -6.98% in the IV. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Pluri Inc 's Revenue growth quarter on quarter, overall rank is 138.


Pluri Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1.02 $ 1.08 $ 1.34 $ 1.33 $ 1.34
Y / Y Revenue Growth (TTM) -23.95 % 4.35 % 97.49 % 121.74 % 309.82 %
Year on Year Revenue Growth Overall Ranking # 65 # 74 # 20 # 69 # 105
Seqeuential Revenue Change (TTM) -5.84 % -19.42 % 0.98 % -0.75 % 29.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 572 # 274 # 286 # 100 # 2423


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Pluri Inc reported a fall in Revenue by -23.95% year on year, to $1 millions, compare to the 4.35% growth at Mar 31 2026.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 65, from total ranking in previous quarter at 74.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 21
Overall # 65

Revenue TTM Y/Y Growth Statistics
High Average Low
701.06 %
 75.64 %
-44.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 127
S&P 500 # 572
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2026 Pluri Inc reported a fall in Revenue by -23.95% year on year, to $1 millions, compare to the 4.35% growth at Mar 31 2026.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 65, from total ranking in previous quarter at 74.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 21
Overall # 65

Revenue TTM Y/Y Growth Statistics
High Average Low
701.06 %
75.64 %
-44.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 127
S&P 500 # 572




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PLUR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Pluri Inc Revenue Growth Rates (PLUR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Pluri Inc (CIK 1158780).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-098862
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Pluri Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.